Ameloblastoma and Ameloid Tumors

Ameloblastoma is a benign but locally aggressive epithelial odontogenic tumor of the jaws, regarded as the prototypical true odontogenic neoplasm. Although it lacks the capacity to form enamel, it arises from enamel-organ-like epithelium and is known for slow, infiltrative growth and a marked tendency to recur if incompletely removed.

Definition

Ameloblastoma is a benign odontogenic epithelial neoplasm composed of proliferating ameloblast-like cells arranged in follicular or plexiform patterns, characteristically showing peripheral palisading and reverse nuclear polarity, with locally invasive growth but no enamel formation.

Scope

This topic covers ameloblastoma and closely related ameloid (enamel-organ-derived) epithelial tumors: their histopathologic subtypes, characteristic radiographic appearance, biologic behavior, recurrence tendency, and the molecular changes increasingly recognized in them. It distinguishes the main clinicopathologic variants, including the conventional solid/multicystic, unicystic, and peripheral forms. The entry is a reference description of the entity and its pathology, not clinical management guidance.

Core questions

• What distinguishes ameloblastoma histologically from other odontogenic lesions?
• How do the solid/multicystic, unicystic, and peripheral variants differ in behavior?
• Why does ameloblastoma have a high tendency to recur?
• What molecular alterations characterize ameloblastoma?

Key concepts

• Ameloblast-like epithelium without enamel formation
• Follicular and plexiform histologic patterns
• Peripheral palisading and reverse nuclear polarity
• Solid/multicystic, unicystic, and peripheral variants
• Locally aggressive, infiltrative growth
• Recurrence after incomplete excision
• BRAF V600E and SMO mutations

Mechanisms

Ameloblastoma arises from odontogenic epithelium with the histologic hallmarks of an enamel organ -- columnar basal cells showing peripheral palisading and reverse polarization around a loosely arranged stellate-reticulum-like core -- but it does not deposit enamel matrix. Its infiltrative behavior, with extension between bony trabeculae beyond the radiographic margin, underlies its propensity to recur after conservative removal. Recurrent activating mutations in the mitogen-activated protein kinase pathway, notably BRAF V600E, and in the sonic hedgehog pathway (SMO) have been identified, linking ameloblastoma development to defined oncogenic signaling, as summarized in the WHO update by Wright and Vered (2017).

Clinical relevance

Ameloblastoma matters because, despite being benign, it can cause extensive jaw destruction and recurs when not fully removed, so completeness of excision strongly influences outcome. Comparative reviews report higher recurrence after conservative than after radical approaches for intraosseous tumors, while acknowledging trade-offs in morbidity. This entry describes why behavior and excision margins matter prognostically and is not a recommendation for any specific procedure in an individual patient.

Epidemiology

Ameloblastoma is among the most frequently diagnosed true odontogenic neoplasms in many surgical series. It most often involves the posterior mandible, presents over a broad adult age range, and the conventional solid/multicystic form classically appears as a multilocular ('soap-bubble') radiolucency, whereas the unicystic variant tends to occur in younger patients and behaves less aggressively.

History

The lesion was historically called adamantinoma, a term abandoned because the tumor does not form enamel ('adamantine' tissue). Successive WHO classifications refined its subtypes, and the 2017 edition consolidated the variants while integrating emerging molecular data such as recurrent BRAF mutations.

Debates

Radical versus conservative surgical management

Resection with a margin lowers recurrence relative to enucleation or curettage but carries greater functional and reconstructive morbidity; meta-analytic evidence shows lower recurrence with radical treatment of intraosseous ameloblastoma, yet the optimal balance for individual variants remains contested.

Key figures

• John M. Wright
• Marilena Vered
• Brad W. Neville
• Robert A. Ord

Seminal works

• wright-2017
• hendra-2019

Frequently asked questions

Is ameloblastoma a cancer?

No. Ameloblastoma is classified as a benign tumor, but it is locally aggressive and infiltrates bone, so it can be destructive and tends to recur if not completely removed; rare malignant counterparts (malignant ameloblastoma and ameloblastic carcinoma) exist but are distinct entities.

Why is ameloblastoma prone to recurrence?

Its epithelium grows infiltratively between bony trabeculae, often extending beyond the margin seen on imaging, so incomplete removal can leave residual tumor that regrows; this is why completeness of excision is emphasized in the literature.